Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This study was designed to evaluate the safety and efficacy of trastuzumab deruxtecan in
HER2-mutated metastatic non-small cell lung cancer (NSCLC) participants who had disease
recurrence or progression during/after at least one regimen of prior anticancer therapy
(second line or later) that must have contained a platinum-based chemotherapy drug.